Figure 2

(A) Histogram analysis in such healthy control and different states of RA (n = 1 for each state). M (marker) 1 is % CFSE of undivided Tconv (an original peak from day 0 of proliferation); M2 is % CFSE of proliferated Tconv. (B) Treg inhibitory activity of in different states of RA (n = 14; remission, n = 13; active state) and (C) in patients categorized by active states according to disease activity score-28 (DAS28) score. Inhibitory activity of Foxp3+ Treg was measured after 3 days co-culture with Tconv cells by flow-cytometry. DAS28 score < 2.6, remission (n = 11); ≥ 2.6–3.2, low disease activity (n = 8); ≥ 3.2–5.0, moderate disease severity (n = 6); ≥ 5.1, high disease severity (n = 2). **p value < 0.01, *** p value < 0.0001 (independent t-test and Kruskal Wallis test). (D) Cross-tabulation analysis for calculating sensitivity, specificity and others indicating RA status statistic. (E and F) The correlation between Treg inhibitory activity and DAS28 score and VAS score (tested by Pearson correlation).